Aleksander Żurakowski

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx, Marco Valgimigli, Peter Jüni et al. · The Lancet · 2018 · 785 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Acute and Late Outcomes of Unprotected Left Main Stenting in Comparison With Surgical Revascularization

Paweł Buszman, Stefan Kiesz, Andrzej Bochenek et al. · Journal of the American College of Cardiology · 2008 · 398 citations

Medicine, Cardiology, Surgery +15

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Left Main Stenting in Comparison With Surgical Revascularization

Paweł Buszman, Paweł Buszman, Iwona Banasiewicz‐Szkróbka et al. · JACC: Cardiovascular Interventions · 2016 · 151 citations

Medicine, Cardiology, Surgery +14